Sai Life Sciences Limited Business Intelligence Report
Sai Life Sciences Limited Business Intelligence Report
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
Sai Life Sciences is an integrated CRDMO providing end-to-end services from discovery to commercial manufacturing. The business has undergone a significant transformation, evolving from a low-margin research firm to a high-margin commercial partner for global pharma. Revenue has scaled from ₹695 Cr in FY19 to ₹2,192 Cr in FY26, showcasing a robust 5-year CAGR of 17.8%. Profitability has seen an even sharper trajectory, with PAT expanding from near-break-even levels in FY22-23 to ₹349 Cr in FY26. Management has successfully navigated the heavy capex cycle required for the pharmaceutical…
Key Changes in FY2026
The business has successfully transitioned from a 1999 start-up to a high-end integrated CRDMO. Over the last decade, it has expanded its reach to serve 19 of the top 25 global pharmaceutical companies, signifying a move up the value chain from simple chemical synthesis to complex discovery and commercial manufacturing. The focus on 'New Modalities' reflects a strategic shift to capture high-value biotechnology contracts beyond traditional small molecules. Recent quarters demonstrate a clear premiumization, with operating margins expanding from 14% in FY23 to 29% in FY26. The evolution is characterized by massive capital expenditure to build a globally competitive research and manufacturing infrastructure.
Management Commentary
Management demonstrates high execution capability, successfully transitioning the company through a multi-year investment phase. The focus on becoming an 'integrated CRDMO' is reflected in the growing number of phase III and commercial molecules. Communication is transparent, with regular earnings calls and detailed investor presentations providing clarity on capacity utilization. The leadership has maintained a stable promoter holding around 34.5% while attracting significant institutional interest. There is a clear strategic push toward digital transformation and premiumization of the service portfolio. Executive compensation appears aligned with profit growth, though specific details on variable pay incentives are prioritized for research milestones.
Financial Highlights
The business exhibits high-quality financial growth, characterized by significant margin expansion. Operating margins have surged from 14% in FY23 to 29% in FY26, driven by higher-value commercial molecules. The latest return ratios are encouraging, with ROCE reaching 18.2% and ROE at 14.0% in FY26, a massive improvement from the low single digits seen three years prior. Revenue growth is consistent, with a 22% 3-year CAGR, indicating successful scale-up of commercial projects. Net profit growth at 42.2% CAGR over 5 years demonstrates strong operating leverage as the company moves up the value chain. However, high P/E multiples reflect substantial market expectations for continued high-double-digit growth.
Major Opportunities
- Significant revenue growth (22% 3Y CAGR)
- Operating margin expansion to 29% in FY26
- ROCE improved from 3.9% (FY22) to 18.2% (FY26)
Major Risks
- Persistent negative Free Cash Flow due to high capex
- Stock trading at 12.4x Book Value
- Working capital days increased to 77.6 days
About Sai Life Sciences Limited's Annual Report & Financial Performance
The latest Sai Life Sciences Limited annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this Sai Life Sciences Limited research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
Sai Life Sciences Limited — Frequently Asked Questions
Explore more Sai Life Sciences Limited research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.